A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders

NCT03432065 | Withdrawn Phase 2 FDA Drug

• 1 other identifier: 2017-P-002731
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The main objective of this exploratory 8-week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. The study results will be used to generate hypotheses for a larger randomized-controlled trial with explicit hypotheses and sufficient statistical power.

Conditions

Autism Spectrum Disorder; Anxiety

Keywords

Autism Spectrum Disorders; Anxiety; Pervasive Developmental Disorders; Buspar; Buspirone

Outcome Measures

Primary Outcomes (1)

• Reduction in Child and Adolescent Symptom Inventory-5-Anxiety (CASI-Anx) Score

  The primary outcome measure of efficacy will be assessed by the reduction in anxiety symptom severity as measured by a change from baseline on the Child and Adolescent Symptom Inventory-5-Anxiety (CASI-Anx) scores. Responders are defined as those who demonstrate a \>30% reduction on the CASI-Anx.

  Baseline to 8 Weeks

Study Arms (1)

Buspirone

EXPERIMENTAL

Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.

Drug: Buspirone

Interventions

Buspirone DRUG

Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.

Buspirone

Eligibility Criteria

• Age: 6 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Male or female participants between 6 and 17 years of age
• DSM-5 ASD diagnostic criteria as established by clinical diagnostic interview
• Participants with a score of ≥60 or more on the Anxiety/Depression subscale of CBCL
• Subjects can be taking psychotropic medications if they have been on the medication for at least 4 weeks prior to initiating study treatment and if they are on a stable dose, provided the medication is not listed in the Concomitant Medications section of the protocol.

You may not qualify if:

• History of active seizure disorder (EEG suggestive of seizure activity and/or history of seizure in last 1 month)
• Subjects with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study, including:
• Pregnant or nursing females
• Organic brain disorders
• Uncorrected hypothyroidism or hyperthyroidism
• Clinically significant abnormalities on ECG (e.g., QT prolongation, arrhythmia)
• History of renal or hepatic impairment.
• Clinically unstable psychiatric conditions or judged to be at serious suicidal risk
• Current diagnosis of schizophrenia or bipolar disorder
• History of substance use (except nicotine or caffeine) within past 3 months or urine drug screen positive for substances of abuse
• Current treatment with medication with primary central nervous system activity (as specified in the Concomitant Medication section of the protocol)
• A non-responder or history of intolerance to buspirone, after treatment at an adequate dose and duration as determined by the clinician
• Subjects currently taking monoamine oxidase inhibitors (MAOI) and/or CYP3A4 inducers or inhibitors including nefazodone, diltiazem, verapamil, erythromaycin, itraconazole, or rifampin.

Sponsors & Collaborators

• Massachusetts General Hospital: lead

MeSH Terms

Conditions

Autism Spectrum Disorder; Anxiety Disorders; Child Development Disorders, Pervasive

Interventions

Buspirone

Condition Hierarchy (Ancestors)

Neurodevelopmental Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Spiro Compounds; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines; Polycyclic Compounds

Study Officials

• Atilla Ceranoglu, MD

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical doctor

Study Record Dates

• First Submitted: February 6, 2018
• First Posted: February 13, 2018
• Study Start: December 1, 2024
• Primary Completion: August 1, 2025
• Study Completion: August 1, 2025
• Last Updated: September 26, 2024

Record last verified: 2024-09